Premium
An effective modestly intensive re‐induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia
Author(s) -
Kaspers Gertjan J. L.,
Niewerth Denise,
Wilhelm Bram A. J.,
Scholtevan Houtem Peggy,
LopezYurda Marta,
Berkhof Johannes,
Cloos Jacqueline,
de Haas Valerie,
Mathôt Ron A.,
Attarbaschi Andishe,
Baruchel André,
de Bont Eveline S.,
Fagioli Franca,
Rössig Claudia,
Klingebiel Thomas,
De Moerloose Barbara,
Nelken Brigitte,
Palumbo Giuseppe,
Reinhardt Dirk,
Rohrlich PierreSimon,
Simon Pauline,
Stackelberg Arend,
Zwaan Christian Michel
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15233
Subject(s) - bortezomib , medicine , vincristine , neutropenia , refractory (planetary science) , dexamethasone , regimen , febrile neutropenia , induction chemotherapy , oncology , chemotherapy , surgery , gastroenterology , multiple myeloma , cyclophosphamide , physics , astrobiology
Summary This trial explored the efficacy of re‐induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.